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Clobetasol propionate (CP) is a potent topical corticosteroid that causes several cutaneous and systemic 
side effects. In the present work, CP was encapsulated in nanostructured lipid carriers (NLCs) to increase 
drug retention in the outer skin layers and improve the safety of topical therapy. NLCs were prepared 
using a microemulsion technique with a mixture of lecithin, taurodeoxycholate, stearic acid, and oleic 
acid. In vitro penetration studies were performed in a modified Franz-type diffusion cell, and porcine 
ears were used as a model of human skin. A simple and sensitive liquid chromatographic method was 
developed and validated for clobetasol determination in different skin layers. NLCs presented uniform 
size distribution, high zeta potentialand entrapment efficiency values (> 98%). The analytical procedure 
was validated according to FDA guidelines. Clobetasol recoveries from skin samples were higher than 
85%, with no interference of skin components and NLC ingredients. In experiments, after 6 h, a higher 
drug accumulation in the stratum corneum arising from NLCs compared to aqueous CP solution was 
observed. Thus, the NLCs demonstrated high potential for targeting CP to the skin and ensuring drug 
accumulation in the stratum corneum.
Uniterms: Clobetasol propionate/in vitro skin penetration. Nanostructured lipid carriers/in vitro study. 
Proprionato de clobetasol (CP) é um potente corticóide tópico, que apresenta vários efeitos adversos 
cutâneos e sistêmicos. No presente trabalho, CP foi encapsulado em carreadores lipídicos nanoestruturados 
(NLCs) visando aumentar a retenção do fármaco nas camadas superficiais da pele e a segurança da terapia 
tópica. NLCs foram preparados usando a técnica de diluição de microemulsão com mistura de lecitina, 
taurodesoxicolato, ácido esteárico e ácido oléico. Estudos de penetração in vitro foram realizados em 
células de difusão de Franz modificadas usando pele de orelha de porco como modelo de pele humana. 
Um método simples e sensível de cromatografia líquida foi desenvolvido e validado para a determinação 
de clobetasol nas diferentes camadas da pele. NLCs apresentaram distribuição de tamanho uniforme e 
valores elevados de potencial zeta e eficiência de encapsulação (>98%). O procedimento analítico foi 
validado de acordo com as diretrizes do FDA. A recuperação de clobetasol a partir das amostras de pele 
foi maior que 85%, sem interferência dos componentes da pele e dos excipientes das NLCs. Após 6 horas 
de experimento observou-se maior acúmulo do fármaco a partir das NLCs comparado à solução aquosa 
de CP. Dessa forma, as NLCs mostraram elevado potencial para direcionar o CP para a pele, pois elas 
possibilitaram o acúmulo do fármaco no estrato córneo. 
Unitermos: Proprionato de clobetasol/penetração cutânea in vitro. Carreadores lipídicos nanoestruturados/
estudo in vitro.
INTRODUCTION
Corticosteroids have been successfully employed 
for the treatment of several inflammatory skin conditions. 
Their clinical efficacy is associated with drug skin reten-
tion; however, they can permeate the stratum corneum, 
reaching deeper skin layers, which may cause local and 
systemic side effects (Zhang, Smith, 2011). Clobetasol 
propionate (CP) is a superpotent topical corticosteroid 
(USA class I as per Stoughton–Cornell classification) 
(Horn et al., 2010). Skin atrophy, skin infections, and 
hypothalamic-pituitary-adrenal (HPA) axis suppression 
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are some of the possible side effects of topical corticoste-
roids, which are related to the clinical potency of the drug 
(Horn et al., 2010).
Improvements in the safety of topical corticosteroid 
therapy may be achieved by drug nanoencapsulation, 
which can increase the drug’s accumulation in the skin 
while minimizing deep drug permeation and adverse sys-
temic effects (Senyigit et al., 2010). CP has been nanoen-
capsulated in lecithin/chitosan nanoparticles (Senyigit et 
al., 2010), polymer-coated lipid nanocapsules (Fontana 
et al., 2011), liposomes (Rao, Murthy, 2005), and lipid 
nanoparticles (Kalariya et al., 2005; Hu et al., 2006). 
In the present work, CP was encapsulated in nano-
structured lipid carriers (NLCs) to increase drug retention 
in the outer skin layers and avoid systemic absorption. 
NLCs are the second generation of lipid nanoparticles 
prepared with blends of solid lipids and oils (Pardeike, 
Homoss, Muller, 2009). These particles were developed 
to increase loading capacity and minimize expulsion of 
active compounds during storage, which are limitations 
of the first generation of lipid nanoparticles. NLCs have 
attracted researchers’ attention due to their small size, high 
drug loading, and biocompatible and biodegradable lipid 
composition. NLCs were produced in this case using a 
simple microemulsion technique, which was previously 
employed by our research group to produce lipid nanopar-
ticles containing the cytotoxic drug topotecan (Souza et 
al., 2011). It is important to note that several papers have 
reported that NLCs have enormous potential to improve 
skin penetration and the retention of drugs in the skin 
(Pardeike, Homoss, Muller, 2009). 
Thus, the purpose of this work was to develop 
clobetasol-loaded NLCs to improve the accumulation of 
the drug in the outer skin layers. We also developed an 
extraction procedure and analytical method that is able 
to quantify CP in both viable and non-viable skin with no 
interference from skin components or NLC ingredients.
MATERIAL AND METHODS
Reagents
Clobetasol propionate (min. 98%) was purchased 
from Sigma-Aldrich (São Paulo, Brazil). Stearic acid 
(mp 58.77 °C, Vetec, Brazil), oleic acid (Sigma–Aldrich, 
Brazil), soy lecithin (Lipoid S100, Germany), and sodium 
taurodeoxycholate (Sigma–Aldrich, Brazil) were used for 
the preparation of the nanostructured lipid nanoparticles. 
Acetonitrile was purchased from J. T. Baker (Phillipsburg, 
USA). Water was purified using a Milli-Q system (Mil-
lipore, Billerica, USA) with a 0.22 μm pore end filter.
Production and characterization of CP-loaded NLCs
CP-loaded NLCs were prepared using a microemul-
sion technique. A mixture of lecithin, taurodeoxycholate, 
stearic acid, and oleic acid was heated, and CP was added 
to the melted material. Then, 250 µL of distilled water 
was added to the mixture under magnetic stirring, and 
a thermodynamically stable microemulsion system was 
formed. The microemulsion was dispersed into cold wa-
ter (2–4 °C) under vigorous stirring (13,400 rpm for 10 
min, IKA T25 Ultra-Turrax, Germany) using a 1:20 ratio 
(microemulsion:water) to form an NLC dispersion. The 
dispersion had a total lipid content of 2% (w/v), stabilized 
by 1.25% (w/v) of surfactant (lecithin: taurodeoxycholate, 
4:1 ratio). The stearic acid: oleic acid ratio in the NLCs 
was 3:1 (Souza et al., 2011). The CP in the formulation 
comprised 4% (w/w) of the lipid content.
Dynamic light scattering was used to assess the 
mean particle size and polydispersity index (PdI) of the 
NLC dispersions. Samples were diluted (1:100) with 
purified water and analyzed using a Zetasizer Nano S 
(Malvern Instruments, UK). Zeta potential was determined 
from electrophoretic mobility using a Zetasizer Nano ZS 
(Malvern Instruments, UK).
Encapsulation efficiency (EE) was determined by 
the ultrafiltration technique (eq. 1). To isolate the en-
trapped CP from free drug, 1 mL of freshly prepared NLC 
dispersion was subjected to ultrafiltration (Vivaspin 2®, 
Sartorius, USA) for 60 min at 4,000 g at 4 °C. Filtrate con-
taining the free drug was withdrawn for HPLC analysis as 
described below. All analyses were performed in triplicate. 
The total amount of drug incorporated in the NLC was 
determined by lipid disruption with acetonitrile followed 
by HPLC quantification. Drug loading and drug recovery 
were calculated according eq. 2 and 3, respectively.
 
  Eq. (1)
  Eq. (2)
 Eq. (3)
In vitro skin penetration studies of free and 
nanoencapsulated clobetasol
CP penetration studies were carried out in a modified 
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Franz-type diffusion cell (Microette; Hanson Research, 
Chatsworth, USA) (Figure 1). The receptor media was a 1% 
(w/v) sodium dodecyl sulfate (SDS) aqueous solution. The 
solubility of CP in the receptor medium was determined 
by addition of an excess of CP to the medium, followed 
by 24 h agitation at 37 °C, filtration and quantitation of 
the dissolved drug. The solubility of CP was 0.47 mg/mL. 
Solutions of CP in 1% (w/v) SDS aqueous solution or 
CP-loaded NLCs were added to the donor media. In both 
cases, 80 μg of CP was used in the donor cell to ensure 
sink conditions. The diffusion area available between the 
receptor and donor compartments was 1.86 cm2. The stir-
ring rate and temperature were maintained at 300 rpm and 
37 °C, respectively. Experiments were performed for 3 h 
and 6 h (n=6). After each experiment, the skin surface was 
washed with deionized water to remove excess CP on the 
skin surface. Washed skin was subjected to drug extraction 
and quantitation as described below. 
Skin sample preparation
Pig ears were used as a model of human skin. The 
material was collected immediately after the slaughter of 
the animals. Ears were then dermatomed in the laboratory. 
Then, the dermatomized skin (700 μm thick) was kept at 
− 80 °C for a maximum of 30 days. After the in vitro pen-
etration study, the stratum corneum (SC) was separated 
from the remaining skin (RS) using the tape-stripping 
technique. Skin was tape-stripped 15 times with adhesive 
tapes (Durex Original 500, 3M, Sumaré, Brazil). Tape 
strips with SC and RS were placed in individual test tubes 
for the extraction procedure.
CP extraction from SC and RS
For the CP recovery studies, blank samples of adhe-
sive tapes with SC were spiked with a solution of CP in ace-
tonitrile and allowed to dry. Dried tapes were then immersed 
in 5 mL of acetonitrile for 20 min to obtain a CP final con-
centration of 50 μg/mL. The mixture was vortexed for 2 min 
and analyzed by HPLC-UV. The RS was also spiked with 
a solution of CP in acetonitrile. Following the evaporation 
of the solvent, 5 mL of acetonitrile was added to the tube. 
The RS was then processed with a tissue homogenizer (T25 
ULTRA-TURRAX®, IKA, Staufen, Germany) for 2 min at 
6,000 rpm, followed by bath sonication (USC 1400, Unique, 
Indaiatuba, Brazil) for 20 min. The skin homogenate was 
then filtered and analyzed by HPLC-UV. CP extraction from 
samples collected during the in vitro penetration studies was 
performed as described above (n=3).
Apparatus and chromatographic conditions
Samples were analyzed with an HPLC system con-
sisting of an isocratic pump (ProStar 210, Varian, Palo 
Alto, USA), autosampler (ProStar 400, Varian, Palo Alto, 
USA), and UV detector (ProStar 325, Varian, Palo Alto, 
USA). Separation was achieved using an Agilent ZOR-
BAX Eclipse XDB-C18 column (250 x 4.6 mm, 5 μm). 
The mobile phase was a 30:70 (v/v) mixture of water and 
acetonitrile. The flow rate was 1.0 mL/min, the injection 
volume was 50 μL, and UV detection was carried out at 
240 nm. Data acquisition was performed using Galaxie 
Chromatography Data System software.
Method validation
The method was developed and validated for linear-
ity, accuracy, precision, and quantitation limit in accor-
dance with the Food and Drug Administration Guidelines 
for the validation of analytical methods (FDA, 2000). 
The selectivity was investigated against formulation 
ingredients, skin endogenous components, and adhesive 
tapes. Blanks of remaining skin and stratum corneum 
tape-stripped from six sources of skin were analyzed for 
the absence of interfering compounds at CP retention 
time. Precision (repeatability and intermediate precision) 
was expressed as the relative standard deviation (RSD%) 
of replicate measurements. Accuracy was calculated as 
the percentage difference between the measured and true 
values. Accuracy was expressed as the relative error of 
measurement (E%). Recovery was determined by comput-
ing the ratio of the amount of CP extracted from spiked 
skin to the amount of CP added.
RESULTS AND DISCUSSION
Method development and validation
CP is the most important corticosteroid in derma-
FIGURE 1 - Schematic representation of a Franz-cell apparatus.
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tological therapy; however, there are few reports on the 
quantitation of CP in skin matrices in the literature (Seny-
igit et al., 2010; Fontana et al., 2011; Rao, Murthy, 2005; 
Kalariya et al., 2005; Weigmann et al., 1999; Mueller, An-
issimov, Roberts, 2003), and there are no published data on 
the development and validation of an analytical procedure 
capable of quantifying CP in both the stratum corneum and 
remaining skin (viable epidermis plus dermis). Literature 
reports on the quantitation of CP in skin are based on iso-
cratic HPLC-RP methods, and analytical separations have 
been performed with water and acetonitrile as the mobile 
phase. However, most of the reports, although focused in 
the application of the method, do not present details on 
method development or analytical validation data.
One of the challenges for quantifying drugs in 
biological matrices is the development of an efficient ex-
traction procedure. This issue is particularly true for skin 
matrices, as the interactions among the analyte, skin lipids, 
and proteins may result in low drug recovery. High drug 
recovery values (above 90% from epidermis and dermis) 
have been reported in the literature (Senyigit et al., 2010). 
Weigmann et al. (1999) developed an exhaustive proce-
dure for CP extraction from human stratum corneum. In 
the present work, the mean recovery rates of CP from por-
cine ear skin were 101.48% (± 5.01) and 86.83% (± 5.20) 
for the stratum corneum and remaining skin, respectively, 
denoting the high efficiency of the extraction procedure 
employed. It is important to note that the procedure pre-
sented here for CP extraction from the stratum corneum 
is simpler and less time consuming compared to some 
previously reported methods (Weigmann et al., 1999).
 A simple method for the separation and quantitation 
of CP in the stratum corneum and remaining skin was also 
developed and validated. Chromatographic conditions re-
sulted in a short run time, with a CP retention time of 6.10 
min. The short run time is suitable for the routine analysis 
of a large number of samples from in vitro penetration 
studies. Typical chromatograms of stratum corneum and 
remaining skin, both spiked and not spiked with CP, are 
presented in Figure 2. As seen, the proposed method was 
able to quantify CP without interference from endogenous 
skin compounds and formulation ingredients, demonstrat-
ing the specificity of the method. 
Validation of the analytical method was performed 
and linearity was found in the concentration range of 
0.5-15 µg/mL (r=0.999). The detection limit (DL) was 
25 ng/mL, and the quantification limit (QL) was 100 ng/
mL, which may be considered suitable for CP quantifica-
tion during in vitro penetration studies. Weigmann et al. 
(1999) reported a detection limit of 160 ng/mL, which is 
far superior to the one reported here.
Accuracy and precision are presented in Table I. All 
values of accuracy and precision were within the accept-
able limits, with E% and RSD% values no greater than 
5% (FDA, 2000).
NLC characterization 
NLCs were prepared with and without CP using the 
microemulsion technique; the characterization data are 
shown in Table II.
CP-loaded nanostructured lipid carriers (NLCs) 
presented low average diameters and low polydispersity 
index (PdI) values, denoting a uniform size distribution. 
No significant differences in mean diameter, PdI, or zeta 
potential were observed in NLCs with or without CP, 
suggesting that the addition of the drug did not alter the 
original characteristics of the nanoparticle dispersion.
The CP-NLCs presented low drug recovery (Table 
II) due to formulation adherence to the experimental ap-
paratus. Therefore, the use of thermostatic devices is ad-
FIGURE 2 - Chromatograms obtained from the analysis of 
clobetasol-spiked or blank stratum corneum (2a) and from 
clobetasol-spiked or blank remaining skin (2b).
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Relative Standard Deviation (RSD%) Relative Error of Measurement (E%)
Days Days
1 2 3 1 2 3
1 4.18 3.00 0.61 3.01 3.71 -2.27
5 1.96 2.96 0.68 -0.22 0.52 -2.71
10 3.05 1.65 0.38  4.89 3.98 -2.24
TABLE II - Mean diameter, polydispersity index (PdI), zeta potential, entrapment efficiency, drug loading, and drug recovery of 





EE% (w/w) DL% (w/w) DR% (w/w)
NLCs 195.5± 17.9 0.22 ±0.05 -49.8 ± 2.5 --- --- ---
CP-NLCs 157.9 ± 19.7 0.19 ±0.01 -53.9 ± 1.1 98.6±0.4 2.34±0.1 62.2±3
visable for the transfer procedure to avoid process losses 
during industrial production of lipid nanoparticles.
Several papers have reported that zeta potential val-
ues greater than 30 mV (in modulus) denote good electro-
static repulsion between the nanoparticles, improving the 
physical stability of the system (Freitas, Mueller, 1998). 
Accordingly, the zeta potential values of the NLCs with 
and without CP (Table II) suggest that these nanoparticle 
dispersions have great physical stability. The entrapment 
efficiency was very high (Table II), which indicates that 
the lipids and surfactants employed were very suitable for 
CP nanoencapsulation.
The application of lipid nanoparticles to the skin 
has been related to several therapeutic benefits, such as 
the improvement of drug penetration, controlled release, 
and excellent tolerability (Pardeike, Homoss, Muller, 
2009). Small nanoparticles, such as those reported here, 
ensure close contact of the drug formulation with the 
stratum corneum and exert occlusive effects, improving 
skin hydration and the penetration of the drug into the skin 
(Pardeike, Homoss, Muller, 2009).
In vitro skin penetration of free and CP-loaded 
lipid nanoparticles
The nanoparticle formulation was added to the donor 
compartment of a Franz-type cell apparatus (Figure 1), and 
CP skin penetration was determined.
In accordance with theoretical expectations, we ob-
served a higher CP accumulation in the stratum corneum 
from lipid nanoparticles compared to accumulation from 
aqueous CP solution (sodium dodecyl sulfate, 1%, w/v) 
after 6 h of experiment (p<0.01) (Figure 3).In contrast, no 
significant differences were observed in SC samples after 
3 hours during the experiment (Figure 3).
Several studies have demonstrated that NLCs can 
increase drug penetration and retention in the skin, likely 
due to the occlusive effect caused by the formation of an 
intact film on the skin surface (Marquelle-Oliveira et al., 
2010). In addition, NLCs may interact with lipids in the 
outermost skin layers, resulting in stratum corneum fluidi-
zation and increased drug penetration. Nanoparticles may 
FIGURE 3 - In vitro clobetasol penetration in porcine ear skin 
stratum corneum after 3 and 6 hours of experimentation.
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also accumulate in skin appendages, such as hair follicles, 
which can act as a long-term reservoir for drug release 
(Knorr et al., 2009). Based on the results presented here, 
it appears that CP-NLCs accumulate on the skin surface, 
promoting a controlled release for periods longer than 3 
hours. It is important to note that no CP was detected in 
the receptor media for all formulations tested after 3 or 6 
h of the in vitro penetration experiment.
There was no significant difference in CP accumula-
tion in the remaining skin 3 or 6 hours after the application 
of the drug-loaded nanoparticles or aqueous dispersions 
(Figure 4). Despite this observation, CP nanoencapsulation 
demonstrated a high potential to improve topical therapy, 
as the stratum corneum may act as a drug reservoir, and 
CP higher accumulation in this layer may lead to high 
CP concentrations in the remaining skin during chronic 
administration schedules. Indeed, nanoencapsulation may 
significantly increase the concentration of drug available 
for skin penetration, particularly for drugs with poor aque-
ous solubility, which dissolve only a small amount in con-
ventional topical vehicles, such as gels and creams. The 
preparation of higher drug-loading CP lipid nanoparticles 
is currently under investigation in our laboratory.
CONCLUSIONS
The NLCs obtained in this work by the microemul-
sion technique demonstrated high potential for targeting 
CP to the skin, as they provide drug accumulation in the 
stratum corneum. We also demonstrated the suitability 
of the analytical method developed here for determining 
CP concentration in two different skin layers, the stratum 
corneum and remaining skin. The method demonstrated 
high sensitivity, specificity, and drug recovery.
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